New use for old drugs? Prospective targets of chloroquines in cancer therapy

Current Drug Targets

Volumn 15, Issue 9, 2014, Pages 843-851

  Vlahopoulos, Spiros ^a   Critselis, Elena ^a   Voutsas, Ioannis F ^b   Perez, Sonia A ^b   Moschovi, Maria ^a   Baxevanis, Constantin N ^b   Chrousos, George P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Autophagy; Cancer; Chloroquine; Immunity; Lysosome

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; PROTEASOME INHIBITOR; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CHEMOKINE RECEPTOR CXCR4; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HUMAN; NEOPLASMS; AGGRESOME; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLONOGENESIS; CYTOTOXICITY; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; METASTASIS; NEOPLASM; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PROTEASOME INHIBITORS;

EID: 84906916536     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140714121514     Document Type: Review

References (123)

1. Sotelo J, Briceño E, López-González MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 337-43.
2. Espina V, Wysolmerski J, Edmiston K, Liotta LA. Attacking breast cancer at the preinvasion stage by targeting autophagy. Womens Health Lond Engl 2013; 9: 157-70.
3. Goldberg SB, Supko JG, Neal JW, et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2012; 7: 1602-8.
4. Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009; 625: 220-33.
5. Misinzo G, Delputte PL, Nauwynck HJ. Inhibition of endosomelysosome system acidification enhances porcine circovirus 2 infection of porcine epithelial cells. J Virol 2008; 82: 1128-35.
6. Lake JR, Van Dyke RW, Scharschmidt BF. Acidic vesicles in cultured rat hepatocytes. Identification and characterization of their relationship to lysosomes and other storage vesicles. Gastroenterology 1987; 92: 1251-61.
7. Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA. Model System to Define Pharmacokinetic Requirements for Antimalarial Drug Efficacy. Sci Transl Med 2013; 5: 205ra135.
8. Townsend KN, Hughson LRK, Schlie K, Poon VI, Westerback A, Lum JJ. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol Rev 2012; 249: 176-94.
9. O'Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369: 307-18.
10. Graves PR, Kwiek JJ, Fadden P, et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 2002; 62: 1364-72.
11. Petri WA Jr. Can a proteomics strategy be used to identify the antimalarial activity of chloroquine? Trends Pharmacol Sci 2003; 24: 210-212; discussion 212-213.
12. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118: 415-22.
13. Leung KKK, Shilton BH. Chloroquine binding reveals flavin redox switch function of quinone reductase 2. J Biol Chem 2013; 288: 11242-51.
14. Livesey KM, Tang D, Zeh HJ, Lotze MT. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs Lond Engl 2000 2009; 10: 1269-79.
15. Lotze MT, Maranchie J, Appleman L. Inhibiting autophagy: a novel approach for the treatment of renal cell carcinoma. Cancer J Sudbury Mass 2013; 19: 341-7.
16. Liu B, Bao J-K, Yang J-M, Cheng Y. Targeting autophagic pathways for cancer drug discovery. Chin J Cancer 2013; 32: 113-20.
17. McAfee Q, Zhang Z, Samanta A, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA 2012; 109: 8253-8.
18. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326-36.
19. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008; 118: 79-88.
20. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010; 15: 243-9.
21. Lambrou GI, Papadimitriou L, Chrousos GP, Vlahopoulos SA. Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: multiple, diverse signals converging on a few key downstream regulators. Mol Cell Endocrinol 2012; 351: 142-51.
22. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567-72.
23. Anchoori RK, Khan SR, Sueblinvong T, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PloS One 2011; 6: e23888.
24. Carew JS, Medina EC, Esquivel JA 2nd, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010; 14: 2448-59.
25. Copland JA, Sheffield-Moore M, Koldzic-Zivanovic N, et al. Sex steroid receptors in skeletal differentiation and epithelial neoplasia: is tissue-specific intervention possible? BioEssays News Rev Mol Cell Dev Biol 2009; 31: 629-41.
26. Pietrocola F, Izzo V, Niso-Santano M, et al. Regulation of autophagy by stress-responsive transcription factors. Semin Cancer Biol 2013; 23: 310-22.
27. Liou HC, Baltimore D. Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol 1993; 5: 477-87.
28. Lee K-H, Jeong J, Yoo C-G. Long-term incubation with proteasome inhibitors(PIs) induces IκBα degradation via the lysosomal pathway in a IκB kinase (IKK)-dependent and IKK-independent manners. J Biol Chem 2013; 288: 32777-86.
29. Chen F, Lu Y, Kuhn DC, et al. Calpain contributes to silicainduced I kappa B-alpha degradation and nuclear factor-kappa B activation. Arch Biochem Biophys 1997; 342: 383-8.
30. Zhang J-Y, Peng C, Shi H, Wang S, Wang Q, Wang J-Z. Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain. J Alzheimers Dis JAD 2009; 16: 39-47.
31. Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitinproteasome pathway for nuclear factor-kappab activation. J Biol Chem 1999; 274: 787-94.
32. Lambrou GI, Vlahopoulos S, Papathanasiou C, et al. Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: Relation to early gene expression. Leuk Res 2009; 33: 1684-95.
33. Du J, Mitch WE, Wang X, Price SR. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B. J Biol Chem 2000; 275: 19661-6.
34. He Y, Xu Y, Zhang C, et al. Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci Signal 2011; 4: ra44.
35. Kang R, Tang D. Autophagy in pancreatic cancer pathogenesis and treatment. Am J Cancer Res 2012; 2: 383-96.
36. Toh PPC, Luo S, Menzies FM, Raskó T, Wanker EE, Rubinsztein DC. Myc inhibition impairs autophagosome formation. Hum Mol Genet 2013; 22: 5237-48.
37. Sakuma Y, Matsukuma S, Nakamura Y, et al. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Investig J Tech Methods Pathol 2013; 93: 1137-46.
38. Dupéré-Richer D, Kinal M, Ménasché V, et al. Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death Dis 2013; 4: e486.
39. Loehberg CR, Strissel PL, Dittrich R, et al. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol 2012; 83: 480-8.
40. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PloS One 2013; 8: e55096.
41. Habeeb BS, Kitayama J, Nagawa H. Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci 2011; 102: 999-1006.
42. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al. The antimalarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Sci Rep 2013; 3: 2469.
43. Sasaki K, Tsuno NH, Sunami E, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010; 10: 370.
44. Misirkic M, Janjetovic K, Vucicevic L, et al. Inhibition of AMPKdependent autophagy enhances in vitro antiglioma effect of simvastatin. Pharmacol Res Off J Ital Pharmacol Soc 2012; 65: 111-9.
45. Kohli L, Kaza N, Lavalley NJ, et al. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells. Neuro-Oncol 2012; 14: 266-77.
46. Shimizu S, Takehara T, Hikita H, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer J Int Cancer 2012; 131: 548-57.
47. Chen N, Eritja N, Lock R, Debnath J. Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in threedimensional culture. Oncogene 2013; 32: 2543-54.
48. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507-11.
49. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011; 71: 3196-201.
50. Janjetovic K, Vucicevic L, Misirkic M, et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPKindependent activation of Akt. Eur J Pharmacol 2011; 651: 41-50.
51. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med 2009; 13: 3644-54.
52. Liu H, Scholz C, Zang C, et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 2012; 32: 1627-37.
53. Lee K-H, Hsu E-C, Guh J-H, et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem 2011; 286: 39247-58.
54. Castillero E, Nieto-Bona MP, Fernández-Galaz C, et al. Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. Am J Physiol Endocrinol Metab 2011; 300: E790-799.
55. Cariello NF, Romach EH, Colton HM, et al. Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol Sci Off J Soc Toxicol 2005; 88: 250-64.
56. Miranda S, González-Rodríguez Á, García-Ramírez M, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol 2012; 227: 2352-62.
57. Kim EL, Wüstenberg R, Rübsam A, et al. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-Oncol 2010; 12: 389-400.
58. Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro-Oncol 2010; 12: 473-81.
59. Harhaji-Trajkovic L, Arsikin K, Kravic-Stevovic T, et al. Chloroquine-mediated lysosomal dysfunction enhances the anticancer effect of nutrient deprivation. Pharm Res 2012; 29: 2249-63.
60. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011; 10: 1533-41.
61. O'Donovan TR, O'Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 2011; 7: 509-24.
62. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544.
63. Vinod V, Padmakrishnan CJ, Vijayan B, Gopala S. "How can I halt thee?" The puzzles involved in autophagic inhibition. Pharmacol Res Off J Ital Pharmacol Soc 2014; 82: 1-8.
64. Li J, Yang B, Zhou Q, et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelialmesenchymal transition. Carcinogenesis 2013; 34: 1343-51.
65. Ghadimi MP, Lopez G, Torres KE, et al. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther 2012; 11: 1758-69.
66. Vyas AR, Hahm E-R, Arlotti JA, et al. Chemoprevention of prostate cancer by d, l-sulforaphane is augmented by pharmacological inhibition of autophagy. Cancer Res 2013; 73: 5985-95.
67. Kim J, Yip MLR, Shen X, et al. Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PloS One 2012; 7: e31004.
68. Van den Broeck A, Vankelecom H, Van Delm W, et al. Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes. PloS One 2013; 8: e73968.
69. Cheng L, Huang Z, Zhou W, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013; 153: 139-52.
70. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. The Prostate 2007; 67: 774-81.
71. Meng S, Xu J, Wu Y, Ding C. Targeting autophagy to enhance oncolytic virus-based cancer therapy. Expert Opin Biol Ther 2013; 13: 863-73.
72. Benayoun L, Gingis-Velitski S, Voloshin T, et al. Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs. Stem Cells Dayt Ohio 2012; 30: 1831-41.
73. Gong C, Bauvy C, Tonelli G, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stemlike/ progenitor cells. Oncogene 2013; 32: 2261-2272, 2272e.1-11.
74. Hellsten R, Johansson M, Dahlman A, Sterner O, Bjartell A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PloS One 2011; 6: e22118.
75. Jonchère B, Bélanger A, Guette C, Barré B, Coqueret O. STAT3 as a new autophagy regulator. JAK-STAT 2013; 2: e24353.
76. Schäfer A, Teufel J, Ringel F, et al. Aldehyde dehydrogenase 1A1-a new mediator of resistance to temozolomide in glioblastoma. Neuro-Oncol 2012; 14: 1452-64.
77. Niso-Santano M, Shen S, Adjemian S, et al. Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. Autophagy 2013; 9: 415-7.
78. Buratta M, Castigli E, Sciaccaluga M, et al. Loss of cardiolipin in palmitate-treated GL15 glioblastoma cells favors cytochrome c release from mitochondria leading to apoptosis. J Neurochem 2008; 105: 1019-31.
79. Balic A, Sørensen MD, Trabulo SM, et al. Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling. Mol Cancer Ther 2014; 13(7): 1758-71.
80. Choi DS, Blanco E, Kim Y-S, et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells Dayt Ohio 2014.
81. Song Y-J, Zhang S-S, Guo X-L, et al. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett 2013; 339: 70-81.
82. Firat E, Weyerbrock A, Gaedicke S, Grosu A-L, Niedermann G. Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells. PloS One 2012; 7: e47357.
83. Chin BB, Hjelemand A, Rich J, et al. Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. Curr Radiopharm 2012; 5: 47-58.
84. Calabretta B, Salomoni P. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52 Suppl 1: 54-9.
85. Evangelisti C, Ricci F, Tazzari P, et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol 2011; 226: 822-31.
86. Montgomery RB, Kurtzberg J, Rhinehardt-Clark A, et al. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant 1990; 5: 395-402.
87. Palmeira dos Santos C, Pereira GJS, Barbosa CMV, Jurkiewicz A, Smaili SS, Bincoletto C. Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine-induced death of leukaemia cells. J Cancer Res Clin Oncol 2014; 140: 909-20.
88. Colunga A, Bollino D, Schech A, Aurelian L. Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔPK oncolytic activity in melanoma. Gene Ther 2014; 21: 371-8.
89. Ratikan JA, Sayre JW, Schaue D. Chloroquine engages the immune system to eradicate irradiated breast tumors in mice. Int J Radiat Oncol Biol Phys 2013; 87: 761-8.
90. Noman MZ, Janji B, Kaminska B, et al. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 2011; 71: 5976-86.
91. Noman MZ, Janji B, Berchem G, Mami-Chouaib F, Chouaib S. Hypoxia-induced autophagy: a new player in cancer immunotherapy? Autophagy 2012; 8: 704-6.
92. Van der Bruggen P, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006; 18: 98-104.
93. Garulli B, Stillitano MG, Barnaba V, Castrucci MR. Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clin Vaccine Immunol CVI 2008; 15: 1497-504.
94. Garulli B, Di Mario G, Sciaraffia E, Accapezzato D, Barnaba V, Castrucci MR. Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo. Vaccine 2013; 31: 1717-24.
95. Fujii S, Mitsunaga S, Yamazaki M, et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci 2008; 99: 1813-9.
96. Liang X, De Vera ME, Buchser WJ, et al. Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 2012; 72: 2791-801.
97. Briceño E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003; 14: e3.
98. Briceño E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 2007; 67: 388-91.
99. Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC. Concurrent whole brain radiotherapy and shortcourse chloroquine in patients with brain metastases: a pilot trial. J Radiat Oncol 2013; 2 (3).
100. Pellegrini P, Strambi A, Zipoli C, et al. Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: Implications for cancer therapies. Autophagy 2014; 10: 562-71.
101. Hjelmeland AB, Wu Q, Heddleston JM, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011; 18: 829-40.
102. Levy JMM, Thompson JC, Griesinger AM, et al. Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors. Cancer Discov 2014.
103. Ma X-H, Piao S-F, Dey S, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014; 124: 1406-17.
104. Rodriguez-Caruncho C, Bielsa Marsol I. Antimalarials in dermatology: mechanism of action, indications, and side effects. Actas Dermo-Sifiliográficas 2014; 105: 243-52.
105. Guan J-L, Simon AK, Prescott M, et al. Autophagy in stem cells. Autophagy 2013; 9: 830-49.
106. Lawrence MG, Taylor RA, Toivanen R, et al. A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc 2013; 8: 836-48.
107. Zhang Q, Zhang J, Jin H, Sheng S. Whole transcriptome sequencing identifies tumor-specific mutations in human oral squamous cell carcinoma. BMC Med Genomics 2013; 6: 28.
108. Wang X, Slebos RJC, Wang D, et al. Protein identification using customized protein sequence databases derived from RNA-Seq data. J Proteome Res 2012; 11: 1009-17.
109. Rossello FJ, Tothill RW, Britt K, et al. Next-generation sequence analysis of cancer xenograft models. PloS One 2013; 8: e74432.
110. Bristol ML, Emery SM, Maycotte P, Thorburn A, Chakradeo S, Gewirtz DA. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 2013; 344: 544-52.
111. Sun K, Guo X-L, Zhao Q, et al. Paradoxical role of autophagy in the dysplastic and tumor-forming stages of hepatocarcinoma development in rats. Cell Death Dis 2013; 4: e501.
112. Kobayashi T, Tanaka T, Toyama-Sorimachi N. How do cells optimize luminal environments of endosomes/lysosomes for efficient inflammatory responses? J Biochem (Tokyo) 2013.
113. Nyati MK, Feng FY, Kanade VD, Nayak R. Chloroquine treatment increases detection of 5-fluorouracil-induced apoptosis index in vivo. Mol Imaging 2006; 5: 148-52.
114. Driscoll JJ, Chowdhury RD. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications. Cancer Lett 2012; 325: 147-54.
115. Hu Y-L, DeLay M, Jahangiri A, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 2012; 72: 1773-83.
116. Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O'Dwyer PJ. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res Off J Am Assoc Cancer Res 2013; 19: 2995-3007.
117. Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2012; 59: 511-7.
118. Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr Blood Cancer 2013; 60: 1447-51.
119. Aguilera D, Mazewski C, Fangusaro J, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg 2013; 29: 589-96.
120. Thomas R, Vane DW, Grosfeld JL, Faught PR. The effect of chloroquine and hyperthermia on murine neuroblastoma. J Pediatr Surg 1990; 25: 929-32.
121. Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 2013; 288: 31761-71.
122. Smith ER, Klein-Schwartz W. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 2005; 28: 437-43.
123. Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 2013; 73: 3-7.